Skip to content

Earnings call

Jubilant Ingrevia Q4 FY25 earnings call: Jubilant Ingrevia Limited's specialty business grew by 15% and its Nutrition business grew by 10% in FY25

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Specialty business grew by 15% and its Nutrition business grew by 10% in FY25.

The numbers management gave

Results

  • Specialty business grew by 15% and its Nutrition business grew by 10% in FY25.
    Show source
    Just to add to what Deepak mentioned, if you see our full year results, our specialty has grown by 15%, our Nutrition has grown double-digit at 10%.
  • The company said pricing in chemical intermediaries at an overall level made its results look muted, while its highlighted growth drivers were performing in line with what it had highlighted earlier.
    Show source
    So, the growth drivers that we have highlighted are continuing firing, it is just that pricing in chemical intermediaries at an overall level makes the results look muted, but the growth drivers are performing in line with what we have highlighted earlier.

What it expects ahead

What management expects

  • The company said EBITDA growth will continue in a very similar trajectory in FY26 and will outpace revenue growth, predominantly because of the portfolio shift and savings initiatives.
    Show source
    So, EBITDA growth will definitely outpace the growth in revenue predominantly because of the portfolio shift as well as the savings initiatives.

What it is building and selling

Projects and capacity

  • Niacinamide plant was commissioned in January, in FY25.
    Show source
    It was commissioned in January.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Deepak Jain: Resham, absolutely right. And if you look at our revenues, just compare it with FY23 revenue with FY25, you will see the Chemical Intermediates revenues have come down to almost Rs.1,000 crore. So, what has happened is we have added new revenue of about Rs.1,000 crore plus through all these investments but that got offset by the decline in Chemical Intermediates, which is what I was saying, on the back of this new capacity, if the total incremental revenue expected were Rs.2,000-2,500 crore, half of that we have achieved, but of course that half got offset by whatever happened in Chemical Intermediates, but the other half of Rs.1,000 crore plus is yet to come, which we are hopin

    Answer, varun gupta

    Varun Gupta: Resham, Varun here. Just to add to what Deepak mentioned, if you see our full year results, our specialty has grown by 15%, our Nutrition has grown double-digit at 10%. So, the growth drivers that we have highlighted are continuing firing, it is just that pricing in chemical intermediaries at an overall level makes the results look muted, but the growth drivers are performing in line with what we have highlighted earlier.

  2. Question

    Resham Jain: Yes, got it. The last question is we saw a very good margin growth this year as a whole. So, the EBITDA grew much faster than revenue. And given that you have cost saving initiatives, should one expect similar momentum in FY26 as well in terms of EBITDA growing faster than revenue?

    Answer, varun gupta

    Varun Gupta: Hi, Resham. So, yes, EBITDA growth will continue in the very similar trajectory. But next year, as Deepak mentioned, for us, we are intending to grow aggressively in 2026. So, EBITDA growth will definitely outpace the growth in revenue predominantly because of the portfolio shift as well as the savings initiatives. So, logically it will be pacing ahead of growth.

  3. Question

    Nitesh Dhoot: Hi, sir. Good evening. Sorry, I joined really late. Not sure if this has already been taken up. So, just needed one clarification. So, the current year's capitalization is only around Rs.200 crore. So, while I think the cash spend was around Rs.400 crore, but most of it is in the agro MPP. So, was that just the agro MPP that has been commercialized or there any other CAPEX is also?

    Answer, varun gupta

    Varun Gupta: So, the total capitalizations is not Rs.200 crore, it's ahead of Rs.365 crore, that is the capitalization. So, this year we have spent north of Rs.350 crore in our CAPEX. And second part of it, cash flow. Cash flow is in two forms; one is what we have capitalized; and second is the capital advances which sit in the balance sheet. So, we are committed to invest in the CAPEX to fund the growth. What was the second part?

  4. Question

    Nitesh Dhoot: No, just wanted to clarify, whether it was just the agro MPP or was there any other commissioning?

    Answer, varun gupta

    Varun Gupta: There is a Niacinamide plant that we have invested in. That was highlighted to start. It was commissioned in January. That was a big CAPEX that we have invested in, In this year, which was commissioned in FY25.

  5. Question

    Gokul Maheshwari: Right, sir. Great. Thank you so much.

    Answer, varun gupta

    Varun Gupta: So, we thank you all for joining this call today. We hope we have been able to answer your queries. For further clarifications, I will request you to contact our Investor Relations team. Thank you once again for your interest in Jubilant Ingrevia Limited. Good evening to all.

Questions about this call

When was the Jubilant Ingrevia Q4 FY25 earnings call transcript filed?
Jubilant Ingrevia filed the transcript with the exchange on 18 May 2025. This page is built from that transcript.
What does this page list?
4 statements from the transcript across 3 topics, 1 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 5 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Jubilant Ingrevia Q4 FY25 concall: Jubilant Ingrevia Limited's specialty business grew by 15% and its Nutrition business grew by 10% in FY25 · DalalOS